Contents
Clinical research in Maine coordinates and supports advancements in the field of medicine. The state’s leading experts are focused on improving diagnostic medicine, personalized care, quality of life, and survival rates.
Health volunteers, such as yourself, serve as a bridge between medical research and development. With your help, experts can develop new methods that can save people of all ages. We are here to help you find clinical trials that can suit your needs.
Clinical Trials For Disease Areas in Maine
Clinical research trials in Maine tackle the most difficult health problems in the U.S., one breakthrough at a time. Some of the most critical areas studied are cancer research, cardiology, neurological disorders, infectious diseases, and psychiatric health.
For example, Maine Medical Center joined two global human clinical trials for a medication that could treat COVID-19. The trials for remdesivir may provide notable results for both severe and moderate coronavirus cases.
Every participant makes a difference. Apply for a clinical trial today and become a part of the latest research. Check out the trial feed below to find out more.
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
Recruiting
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-sma... Read More
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/29/2024
Locations: Harold Alfond Center for Cancer Care, Augusta, Maine +13 locations
Harold Alfond Center for Cancer Care, Augusta, Maine
Eastern Maine Medical Center, Bangor, Maine
Waldo County General Hospital, Belfast, Maine
MaineHealth/SMHC Cancer Care and Blood Disorders-Biddeford, Biddeford, Maine
Lafayette Family Cancer Center-EMMC, Brewer, Maine
Maine Center for Cancer Medicine-Kennebunk, Kennebunk, Maine
Stephens Memorial Hospital, Norway, Maine
Mercy Hospital, Portland, Maine
Penobscot Bay Medical Center, Rockport, Maine
MaineHealth/SMHC Cancer Care and Blood Disorders-Sanford, Sanford, Maine
Maine Center for Cancer Medicine-Scarborough, Scarborough, Maine
Maine Medical Center- Scarborough Campus, Scarborough, Maine
Maine Medical Partners - South Portland, South Portland, Maine
Maine Center for Cancer Medicine-Topsham, Topsham, Maine
Conditions: ALK Gene Rearrangement, ALK Gene Translocation, ALK Positive, Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7
Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors
Recruiting
This is a multi-center, open-label, first-in-human Phase 1 study evaluating the anti-programmed death receptor 1 (anti-PD-1) antibody dostarlimab (also known as TSR-042) n participants with advanced solid tumors who have limited available treatment options. The study will be conducted in 2 parts with Part 1 consisting of safety evaluation, pharmacokinetics (PK), and pharmacodynamics (PDy) of escalating doses of dostarlimab. Dose escalation will be based on ascending weight-based dose levels (DLs... Read More
This is a multi-center, open-label, first-in-human Phase 1 study evaluating the anti-programmed death receptor 1 (anti-PD-1) antibody dostarlimab (also known as TSR-042) n participants with advanced solid tumors who have limited available treatment options. The study will be conducted in 2 parts with Part 1 consisting of safety evaluation, pharmacokinetics (PK), and pharmacodynamics (PDy) of escalating doses of dostarlimab. Dose escalation will be based on ascending weight-based dose levels (DLs) of dostarlimab and will continue until the maximum tolerated dose (MTD) is reached or may be stopped at any dose level up to the highest dose of 20 milligrams per kilograms (mg/kg) based on emerging safety and PK/PDy data. Part 2 will be conducted in two subparts, Part 2A (fixed-dose safety evaluation cohorts) and Part 2B (expansion cohorts). Part 2A of the study will evaluate the safety and tolerability of dostarlimab at fixed doses of 500 mg administered every 3 weeks (Q3W) and 1000 mg administered every 6 weeks (Q6W). Part 2B of the study will examine the safety and clinical activity of dostarlimab in cohorts of participants with specific types of advanced solid tumors. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/28/2025
Locations: GSK Investigational Site, Scarborough, Maine
GSK Investigational Site, Scarborough, Maine
Conditions: Neoplasms
Studies of Neuregulin/ERBB Signaling in Human Heart
Recruiting
This study examines the role of the epidermal growth factor (EGF) receptor family and the EGF family of ligands in the regulation of non-myocytes isolated from the human heart.
This study examines the role of the epidermal growth factor (EGF) receptor family and the EGF family of ligands in the regulation of non-myocytes isolated from the human heart. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/31/2025
Locations: Maine Medical Center, Portland, Maine
Maine Medical Center, Portland, Maine
Conditions: Heart Disease, Vascular Disease, Heart Failure
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
Recruiting
This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the body. Addition of prostate removal surgery or radiation therapy to standard systemic therapy for prostate cancer may lower the chance of the cancer growing or spreading.
This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the body. Addition of prostate removal surgery or radiation therapy to standard systemic therapy for prostate cancer may lower the chance of the cancer growing or spreading. Read Less
Gender:
MALE
Ages:
18 years and above
Trial Updated:
08/14/2024
Locations: MaineHealth Coastal Cancer Treatment Center, Bath, Maine +5 locations
MaineHealth Coastal Cancer Treatment Center, Bath, Maine
Lafayette Family Cancer Center-EMMC, Brewer, Maine
Maine Medical Center-Bramhall Campus, Portland, Maine
MaineHealth Cancer Care Center of York County, Sanford, Maine
MaineHealth/SMHC Cancer Care and Blood Disorders-Sanford, Sanford, Maine
Maine Medical Center- Scarborough Campus, Scarborough, Maine
Conditions: Castration Levels of Testosterone, Metastatic Prostatic Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Brain Oxygen Optimization in Severe TBI, Phase 3
Recruiting
BOOST3 is a randomized clinical trial to determine the comparative effectiveness of two strategies for monitoring and treating patients with traumatic brain injury (TBI) in the intensive care unit (ICU). The study will determine the safety and efficacy of a strategy guided by treatment goals based on both intracranial pressure (ICP) and brain tissue oxygen (PbtO2) as compared to a strategy guided by treatment goals based on ICP monitoring alone. Both of these alternative strategies are used in s... Read More
BOOST3 is a randomized clinical trial to determine the comparative effectiveness of two strategies for monitoring and treating patients with traumatic brain injury (TBI) in the intensive care unit (ICU). The study will determine the safety and efficacy of a strategy guided by treatment goals based on both intracranial pressure (ICP) and brain tissue oxygen (PbtO2) as compared to a strategy guided by treatment goals based on ICP monitoring alone. Both of these alternative strategies are used in standard care. It is unknown if one is more effective than the other. In both strategies the monitoring and goals help doctors adjust treatments including the kinds and doses of medications and the amount of intravenous fluids given, ventilator (breathing machine) settings, need for blood transfusions, and other medical care. The results of this study will help doctors discover if one of these methods is more safe and effective. Read Less
Gender:
ALL
Ages:
14 years and above
Trial Updated:
12/06/2024
Locations: Maine Medical Center, Portland, Maine
Maine Medical Center, Portland, Maine
Conditions: Brain Injuries, Traumatic
Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17
Recruiting
This is a phase II study using risk and response-adapted therapy for low, intermediate and high risk classical Hodgkin lymphoma. Chemotherapy regimens will be based on risk group assignment. Low-risk and intermediate- risk patients will be treated with bendamustine, etoposide, Adriamycin® (doxorubicin), bleomycin, Oncovin® (vincristine), vinblastine, and prednisone (BEABOVP) chemotherapy. High-risk patients will receive Adcetris® (brentuximab vedotin), etoposide, prednisone and Adriamycin® (doxo... Read More
This is a phase II study using risk and response-adapted therapy for low, intermediate and high risk classical Hodgkin lymphoma. Chemotherapy regimens will be based on risk group assignment. Low-risk and intermediate- risk patients will be treated with bendamustine, etoposide, Adriamycin® (doxorubicin), bleomycin, Oncovin® (vincristine), vinblastine, and prednisone (BEABOVP) chemotherapy. High-risk patients will receive Adcetris® (brentuximab vedotin), etoposide, prednisone and Adriamycin® (doxorubicin) (AEPA) and cyclophosphamide, Adcetris® (brentuximab vedotin), prednisone and Dacarbazine® (DTIC) (CAPDac) chemotherapy. Residual node radiotherapy will be given at the end of all chemotherapy only to involved nodes that do not have an adequate response (AR) after 2 cycles of therapy for all risk groups. Read Less
Gender:
ALL
Ages:
25 years and below
Trial Updated:
02/06/2025
Locations: Maine Children's Cancer Program, Scarborough, Maine
Maine Children's Cancer Program, Scarborough, Maine
Conditions: Hodgkin Lymphoma
Dissemination of the Donor Application: Utilizing Social Media to Identify Potential Live Organ Donors
Recruiting
This study utilizes a web-based application to help patients on the organ transplant waitlist communicate patient's need for a living donor via social media and provide interested potential donors the opportunity to engage with the evaluation process.
This study utilizes a web-based application to help patients on the organ transplant waitlist communicate patient's need for a living donor via social media and provide interested potential donors the opportunity to engage with the evaluation process. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/05/2024
Locations: Maine Medical Center, Portland, Maine
Maine Medical Center, Portland, Maine
Conditions: End Stage Renal Disease, End Stage Liver Disease
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
Recruiting
This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protocol (Lung-MAP). The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned to compare new targeted cancer therapy, designed to block the growth and spread of cancer, or combinations to standard of... Read More
This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protocol (Lung-MAP). The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned to compare new targeted cancer therapy, designed to block the growth and spread of cancer, or combinations to standard of care therapy with the ultimate goal of being able to approve new targeted therapies in this setting. In addition, the protocol includes non-match sub-studies which will include all screened patients not eligible for any of the biomarker-driven sub-studies. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/12/2025
Locations: Harold Alfond Center for Cancer Care, Augusta, Maine +8 locations
Harold Alfond Center for Cancer Care, Augusta, Maine
Eastern Maine Medical Center, Bangor, Maine
Waldo County General Hospital, Belfast, Maine
MaineHealth/SMHC Cancer Care and Blood Disorders-Biddeford, Biddeford, Maine
Lafayette Family Cancer Center-EMMC, Brewer, Maine
Stephens Memorial Hospital, Norway, Maine
Penobscot Bay Medical Center, Rockport, Maine
MaineHealth/SMHC Cancer Care and Blood Disorders-Sanford, Sanford, Maine
Maine Medical Partners - South Portland, South Portland, Maine
Conditions: Previously Treated Non-Small Cell Lung Cancer
Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG
Recruiting
The primary objective of this study is to evaluate the effectiveness (prevention of thromboembolic events) and safety (major bleeding) of adding oral anticoagulation (OAC) to background antiplatelet therapy in patients who develop new-onset post-operative atrial fibrillation (POAF) after isolated coronary artery bypass graft (CABG) surgery.
All patients with a qualifying POAF event, who decline randomization, will be offered the option of enrollment in a parallel registry that captures their ba... Read More
The primary objective of this study is to evaluate the effectiveness (prevention of thromboembolic events) and safety (major bleeding) of adding oral anticoagulation (OAC) to background antiplatelet therapy in patients who develop new-onset post-operative atrial fibrillation (POAF) after isolated coronary artery bypass graft (CABG) surgery.
All patients with a qualifying POAF event, who decline randomization, will be offered the option of enrollment in a parallel registry that captures their baseline risk profile and their treatment strategy in terms of anticoagulants or antiplatelets received. These patients will also be asked to fill out a brief decliner survey. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/05/2025
Locations: Maine Medical Center, Portland, Maine
Maine Medical Center, Portland, Maine
Conditions: Atrial Fibrillation, Stroke, Bleeding
Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL
Recruiting
The purpose of this study is to evaluate the efficacy and safety of acalabrutinib in combination with venetoclax and acalabrutinib in combination with venetoclax with and without obinutuzumab compared to chemoimmunotherapy in subjects with previously untreated CLL.
The purpose of this study is to evaluate the efficacy and safety of acalabrutinib in combination with venetoclax and acalabrutinib in combination with venetoclax with and without obinutuzumab compared to chemoimmunotherapy in subjects with previously untreated CLL. Read Less
Gender:
All
Ages:
Between 18 years and 130 years
Trial Updated:
01/14/2022
Locations: Research Site, Scarborough, Maine
Research Site, Scarborough, Maine
Conditions: Chronic Lymphocytic Leukemia
Paid Clinical Trials in Maine
People who participate in paid clinical trials receive compensation for their efforts. The amount ranges based on the study’s duration and requirements. Every study will provide you with compensation details.
Paid clinical trials come with other benefits as well. All necessary study-related healthcare and medications are provided free of charge. By participating, you help doctors evaluate the potency of a new drug, compare it to other medications, and gain valuable insight.
Clinical Trials For Health Volunteers in Maine
Research teams in Maine are looking for specific volunteers based on the condition and drug they study. Phase 1 studies usually require healthy volunteers. However, some may involve patients with a certain health condition, like cancer, liver disease, or HIV. Check the requirements of the study you are interested in before you apply.
Here is a list of the currently available and upcoming clinical research trials near you.
No trials could be found at this time
Medical Discoveries and Innovation in Maine
Maine research institutions have made remarkable contributions to medical science. Their ingenuity and dedication drive progress and benefit patients from all around the world. Some of their achievements deserve special notice. Like:
- Lyme Disease Research: Maine has a tracking program that shows the water quality in a well. The program displays town-level measures, which come from data collected from over 11,000 water tests. This tracking data can boost prevention and promote early detection of Lyme disease.
- Limb Regeneration Research: Scientists at the Mount Desert Island Biological Laboratory in Bar Harbor, Maine, have made remarkable progress in studying limb regeneration in certain amphibians. Their research can be highly beneficial for regenerative medicine in humans.
- Diabetes Research: The Jackson Laboratory has been instrumental in studying diabetes through genetic research. Their clinical trials provide insight into the genetic factors that influence the disease.
Why Maine Is A Great Place For Clinical Research
Maine clinical research relies heavily on volunteers. Data indicates that most of its residents (92.5%) are white, 2% are Hispanic, 1.8% are multiracial, 1.7% are black, 1.3% are Asian, and 0.6% are American Indian.